Financials in USD. Standardized financial statements.
A compact view of how Voyageur Pharmaceuticals Ltd. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $11,671 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $1.23M | $0 | $2,185 | $2,908 | $2,246 | $1,483 | $2,120 | $0 | $0 | $113,536 |
| Gross Profit? | -$1.22M | $0 | -$2,185 | -$2,908 | -$2,246 | -$1,483 | -$2,120 | $0 | $0 | -$113,536 |
| Gross Margin? | -10466.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $2.31M | $1,513 | $1.22M | $1.75M | $2.05M | $1.00M | $554,893 | $866,028 | $655,742 | $52,323 |
| Operating Income? | -$3.53M | -$1,513 | -$1.22M | -$1.75M | -$1.97M | -$848,939 | -$554,893 | -$1.15M | -$615,363 | -$52,323 |
| EBITDA? | -$3.53M | -$1,513 | -$1.22M | -$1.75M | -$2.04M | -$1.12M | -$550,173 | $0 | $0 | -$520 |
| Income Before Tax | -$3.53M | -$1,707 | -$1.40M | -$1.75M | -$2.05M | -$1.14M | -$552,293 | -$555,860 | -$670,752 | -$52,323 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$444,434 | $0 | -$5,490 |
| Net Income? | -$3.53M | -$1,707 | -$1.40M | -$1.75M | -$2.05M | -$1.14M | -$552,293 | -$555,860 | -$670,752 | -$52,323 |
| EPS? | $-0.02 | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.02 | $-0.01 | $-0.01 | $-0.02 | $-0.05 |
| Diluted EPS? | $-0.02 | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.02 | $-0.01 | $-0.01 | $-0.02 | $-0.05 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality